

CLINICS-D-26-00163_ Supplementary Material**Supplementary Table S1** Clinical characteristics, symptom burden, and medication burden (LC/PASC vs. FM-only; FM first visits only).

Measure	LC/PASC	FM-only (first visits)	SMD (LC-FM)
Age, years	48.4 ± 14.1 (n = 52)	42.1 ± 13.9 (n = 590)	0.45
Female, n (%)	40/54 (74.1%)	548/591 (92.7%)	-0.50
BMI, kg/m ²	29.7 ± 8.9 (n = 42)	31.1 ± 8.9 (n = 566)	-0.15
FIQR (or SIQR-equivalent)	33.0 ± 20.6 (n = 42)	52.9 ± 19.2 (n = 492)	-1.00
Beck Depression Inventory (BDI)	14.2 ± 5.9 (n = 43)	20.3 ± 10.5 (n = 481)	-0.71
Central Sensitization Inventory (CSI)	55.1 ± 16.9 (n = 43)	62.2 ± 14.3 (n = 477)	-0.45
McGill Pain Questionnaire (MPQ)	83.4 ± 51.8 (n = 43)	92.8 ± 46.7 (n = 475)	-0.19
VAS pain (0–10)	3.4 ± 1.9 (n = 43)	5.7 ± 2.1 (n = 576)	-1.17
Total medications identified (free-text)	1.4 ± 1.5 (n = 54)	2.2 ± 1.4 (n = 591)	-0.53
Centrally acting medication classes (count)	1.2 ± 1.4 (n = 54)	1.9 ± 1.3 (n = 586)	-0.54
Any centrally acting agent, n (%)	38/54 (70.4%)	511/586 (87.2%)	-0.41
≥2 centrally acting agents, n (%)	21/54 (38.9%)	349/586 (59.6%)	-0.41

Supplementary Table S2 Comparison of LC/PASC participants with complete versus incomplete SF-36 data.

Measure	Complete SF-36 (n = 43)	Incomplete SF-36 (n = 11)
Age, years	51.9 ± 12.0 (n = 42)	42.9 ± 14.2 (n = 10)
Female, n (%)	27/42 (64.3%)	7/11 (63.6%)
BMI, kg/m ²	30.6 ± 9.5 (n = 31)	25.7 ± 4.7 (n = 11)
FIQR/SIQR-equivalent	48.6 ± 18.1 (n = 36)	32.4 ± 27.0 (n = 6)
Beck Depression Inventory (BDI)	19.0 ± 10.2 (n = 43)	Not available
Central Sensitization Inventory (CSI)	54.8 ± 16.4 (n = 43)	Not available
McGill Pain Questionnaire (MPQ)	65.3 ± 37.7 (n = 43)	Not available